JP2016515628A5 - - Google Patents

Info

Publication number

JP2016515628A5

JP2016515628A5 JP2016506653A JP2016506653A JP2016515628A5 JP 2016515628 A5 JP2016515628 A5 JP 2016515628A5 JP 2016506653 A JP2016506653 A JP 2016506653A JP 2016506653 A JP2016506653 A JP 2016506653A JP 2016515628 A5 JP2016515628 A5 JP 2016515628A5

Authority

JP

Japan

Prior art keywords

compound

combination

empty stomach

once

administered

Prior art date

2014-04-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 210000002784 stomach Anatomy 0.000 claims description 31
• 229940125904 compound 1 Drugs 0.000 claims description 21
• 229940125782 compound 2 Drugs 0.000 claims description 19
• 150000001875 compounds Chemical class 0.000 claims description 10
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 125000001475 halogen functional group Chemical group 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 229960004618 prednisone Drugs 0.000 claims description 4
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
• 150000003839 salts Chemical class 0.000 claims description 4
• 230000000405 serological effect Effects 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 3
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
• 206010060862 Prostate cancer Diseases 0.000 claims description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
• 201000010099 disease Diseases 0.000 claims description 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
• AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 2
• 229960005205 prednisolone Drugs 0.000 claims description 2
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
• 239000013066 combination product Substances 0.000 claims 1
• 229940127555 combination product Drugs 0.000 claims 1
• 229940102542 prednisone 5 mg Drugs 0.000 claims 1
• 159000000021 acetate salts Chemical class 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1